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Background: Giant cell myocarditis (GCM) is a rare disorder in which survival beyond 1 year without heart transplantation is uncommon. The long 
term clinical course of patients with GCM who survive more than 1 year without transplantation is not known.
Methods: We identified 26 patients with biopsy proven GCM from a multicenter GCM registry who survived more than 1 year without heart 
transplantation. The incidence of death, transplantation, ventricular assist device placement and histologically proven disease recurrence was 
ascertained retrospectively. The rates of recurrent heart failure, ventricular arrhythmias, renal failure, and infectious complications were calculated.
Results: The mean age of the cohort was 51.6+/-14.1 yr. with 10 males and 16 females. The average duration of follow up was 5.4 years (range 
1.0 to 16.6). There were 3 deaths (11.5%), 5 heart transplantations (19.2%), and 1 VAD placement (4%). 3 histologically confirmed recurrences 
of GCM (11.5%) occurred between 1.5 and 8 years after diagnosis. 2 of the 3 recurrences occurred in patients who recently discontinued 
immunosuppression. Fifty percent of the cohort (13/26) experienced a total of 29 heart failure episodes more than 1 year after initial diagnosis. 
There were 30 episodes of elevated creatinine in 12 patients, 42 infectious events in 13 patients, and 20 episodes of ventricular arrhythmias in 6 
patients. Overall mortality after year 1 was greater in those patients who received 0 or 1 immunosuppressive drugs than in those who received 2 or 
more in drugs in the first year after GCM diagnosis. (p=.027)
Conclusions: Our data suggest that patients diagnosed with GCM who survive more than 1 year have nearly a 50% combined risk of death, 
transplantation, VAD placement and histologically confirmed disease recurrence. The risk of GCM recurrence continues to at least 8 years after 
diagnosis.
